SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Bought by Schroder Investment Management Group

Schroder Investment Management Group lifted its stake in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 93.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 168,209 shares of the company’s stock after acquiring an additional 81,314 shares during the period. Schroder Investment Management Group owned 0.23% of SpringWorks Therapeutics worth $6,113,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. boosted its holdings in shares of SpringWorks Therapeutics by 13.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 602,227 shares of the company’s stock valued at $19,295,000 after purchasing an additional 73,613 shares during the last quarter. Quantbot Technologies LP purchased a new position in shares of SpringWorks Therapeutics in the 3rd quarter worth $147,000. Verition Fund Management LLC boosted its holdings in SpringWorks Therapeutics by 101.8% in the third quarter. Verition Fund Management LLC now owns 17,500 shares of the company’s stock valued at $561,000 after acquiring an additional 8,826 shares during the last quarter. Edgestream Partners L.P. purchased a new stake in SpringWorks Therapeutics during the third quarter valued at about $278,000. Finally, Quarry LP increased its stake in SpringWorks Therapeutics by 20.0% during the third quarter. Quarry LP now owns 6,000 shares of the company’s stock worth $192,000 after acquiring an additional 1,000 shares during the last quarter.

SpringWorks Therapeutics Stock Down 9.2 %

Shares of NASDAQ:SWTX opened at $39.09 on Friday. The company has a 50 day moving average of $48.71 and a two-hundred day moving average of $39.94. SpringWorks Therapeutics, Inc. has a 52-week low of $28.21 and a 52-week high of $62.00. The company has a market capitalization of $2.93 billion, a price-to-earnings ratio of -11.23 and a beta of 0.79.

SpringWorks Therapeutics (NASDAQ:SWTX) last released its quarterly earnings results on Thursday, February 20th. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.38). The firm had revenue of $61.55 million for the quarter, compared to analyst estimates of $60.53 million. SpringWorks Therapeutics had a negative net margin of 134.73% and a negative return on equity of 46.74%. On average, equities analysts anticipate that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current year.

Insider Activity

In other SpringWorks Therapeutics news, insider Bhavesh Ashar sold 1,016 shares of the stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $61.19, for a total transaction of $62,169.04. Following the transaction, the insider now directly owns 62,053 shares in the company, valued at $3,797,023.07. This represents a 1.61 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Daniel Pichl sold 29,750 shares of the firm’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $54.36, for a total transaction of $1,617,210.00. Following the transaction, the insider now directly owns 50,762 shares of the company’s stock, valued at approximately $2,759,422.32. This represents a 36.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 440,766 shares of company stock worth $24,402,956 over the last ninety days. Corporate insiders own 7.61% of the company’s stock.

Analyst Upgrades and Downgrades

SWTX has been the topic of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $74.00 price objective on shares of SpringWorks Therapeutics in a research note on Friday, February 21st. Wedbush reiterated an “outperform” rating and set a $81.00 price objective on shares of SpringWorks Therapeutics in a research note on Thursday, February 20th. Evercore ISI increased their price objective on shares of SpringWorks Therapeutics from $60.00 to $65.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 12th. Finally, Guggenheim reduced their target price on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $73.20.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.